Navigation Links
CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders' Equity

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), reported today that its Annual Report on Form 10-K included an audit opinion with a "going concern" qualification. The going-concern qualification is a statement from CryoCor's independent registered public accounting firm expressing substantial doubt, based upon current financial resources, as to whether CryoCor can continue to meet its obligations beyond 2008 without access to additional working capital. In its Annual Report on Form 10-K, CryoCor indicated that its working capital balance at December 31, 2007 and the expected collection of $4.0 million from its collaboration with Boston Scientific Corporation, or BSC, would be sufficient to meet its anticipated cash requirements until the fourth quarter of 2008. The Company stated that additional capital would be needed to fund operations beyond that time period. CryoCor has previously announced that it is considering alternative financing options, including public or private equity offerings, debt financings or corporate collaboration and licensing arrangements.

CryoCor also announced today that it received a letter, dated March 26, 2008, from The Nasdaq Stock Market, notifying CryoCor that, based on its Form 10-K for the period ended December 31, 2007, Nasdaq staff determined that CryoCor's stockholders' equity was $6,346,000 as of December 31, 2007 and therefore does not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing on The Nasdaq Global Market set forth in Nasdaq Marketplace Rule 4450(a)(3).

The Nasdaq letter dated March 26, 2008 has no immediate effect on the listing of the Company's common stock. The Nasdaq staff is reviewing CryoCor's eligibility for continued listing on The Nasdaq Global Market and has asked the Company to provide a specific plan to achieve and sustain compliance with all of the Nasdaq listing requirements by April 10, 2008. The Company intends to respond formally to the Nasdaq request for a plan on or before the April 10, 2008 deadline.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, the Cryoablation System has been approved for the treatment of right atrial flutter and CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation. For more information please visit the Company's website at

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements included in this press release related to CryoCor's ability to obtain financing or enter into a corporate partnership, the period of time over which CryoCor expects its existing cash resources, together with the additional cash that it expects to receive from BSC, to fund the Company, and CryoCor's ability to meet the Nasdaq stockholders' equity requirement and other Nasdaq listing requirements in the future, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's ability to fund its operations until the fourth quarter of 2008, and to obtain additional capital to continue to fund its operations beyond that time period; risks associated with CryoCor's ability to meet the Nasdaq stockholders' equity requirement and other Nasdaq listing requirements in the future; risks associated with its ongoing legal actions with CryoCath Technologies, Inc., which include the declared patent interference and the ongoing United States International Trade Commission investigation risks associated with CryoCor's ability to successfully commercialize its Cryoablation System in the United States and elsewhere; risks associated with CryoCor's dependence on patents and proprietary rights; risks associated with CryoCor's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; and the other risks and uncertainties identified in CryoCor's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. CryoCor expressly disclaims any intent or obligation to update any of these forward- looking statements.


CryoCor The Ruth Group

Gregory J. Tibbitts Zack Kubow (investors)

Chief Financial Officer (646) 536-7020

(858) 909-2200

Jason Rando (media)

(646) 536-7025

SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
2. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
3. CryoCor Appoints New Vice President of Sales and Marketing
4. CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
5. CryoCor Files Response to Patent Infringement Lawsuit
6. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
7. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
8. Dr. Warren Jackman Joins CryoCor Scientific Advisory Board
9. CryoCor to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
10. CryoCor Announces Web cast and Conference Call of 2007 Year End Results
11. CryoCor Reports 2007 Results
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official ... independent group of Microsoft Dynamics SL software users, partners, industry experts and representatives. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: